NCT03086356View on ClinicalTrials.gov

Study to Investigate the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Idarucizumab in Chinese Healthy Male and Female Volunteers Who Had Taken Dabigatran Etexilate and Whose Plasma Concentrations of Dabigatran Were at or Close to Steady State

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 10, 2017

Primary Completion Date

September 12, 2017

Study Completion Date

September 12, 2017

Conditions
Healthy Volunteers
Interventions
DRUG

Dabigatran etexilate

Days 1-4 and Day 8-11

DRUG

Idarucizumab

Day 11

Trial Locations (1)

100034

Peking University First Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT03086356 - Study to Investigate the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Idarucizumab in Chinese Healthy Male and Female Volunteers Who Had Taken Dabigatran Etexilate and Whose Plasma Concentrations of Dabigatran Were at or Close to Steady State | Biotech Hunter | Biotech Hunter